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monotherapy. In this review, we discuss the latest results 
from trials assessing talimogene laherparepvec in combi-
nation with other immunotherapies, provide an overview 
of ongoing and upcoming combination trials, and suggest 
future directions for talimogene laherparepvec in combina-
tion therapy for solid tumors.
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Abbreviations
AE  Adverse events
CR  Complete response
DCR  Disease control rate
DLT  Dose-limiting toxicity
DOR  Duration of response
DRR  Durable response rate
EAC  Endpoint-assessment committee
FDA  Food and Drug Administration
GM-CSF  Granulocyte–macrophage colony-stimulating 
factor
HR  Hazard ratio
HSV-1  Herpes simplex virus type 1
ICOS  Inducible T-cell costimulator
ORR  Overall response rate
PD  Progressive disease
PFS  Progression-free survival
PKR  Protein kinase R
PR  Partial response
SCCHN  Squamous cell carcinoma of the head and neck
STING  Stimulator of interferon genes
TTR  Time to response
Abstract Talimogene laherparepvec is a first-in-class 
intralesional oncolytic immunotherapy. In a recent Phase 
III trial (OPTiM), talimogene laherparepvec significantly 
improved durable response rate compared with subcuta-
neous granulocyte–macrophage colony-stimulating factor 
(GM-CSF). Overall response rate was also higher in the 
talimogene laherparepvec arm, and the greatest efficacy 
was demonstrated in patients with earlier-stage (IIIB, IIIC, 
or IVM1a) melanoma. Talimogene laherparepvec was well 
tolerated, with the majority (89%) of adverse events being 
grade 1 or 2. Preclinical studies have shown that talimogene 
laherparepvec exerts antitumor activity by selectively repli-
cating within and destroying cancer cells, and through the 
release of tumor-associated antigens and expression of GM-
CSF, which facilitates a wider antitumor immune response. 
It is hypothesized that combining talimogene laherparepvec 
with a systemic immunotherapy may, by bringing together 
complementary mechanisms of action, further enhance the 
efficacy of both agents. Indeed, talimogene laherparepvec 
is currently being assessed in combination with immune 
checkpoint inhibitors, including ipilimumab and pembroli-
zumab, in trials for melanoma and other solid tumors. Early 
results in melanoma indicate that the combination of tali-
mogene laherparepvec with ipilimumab or pembrolizumab 
has greater efficacy than either therapy alone, without 
additional safety concerns above those expected for each 
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Introduction
Talimogene laherparepvec is a first-in-class intralesional 
oncolytic viral therapy that, based on data from the recent 
Phase III Oncovex (GM-CSF) Pivotal Trial in Melanoma 
(OPTiM) trial in stage IIIB–IVM1c melanoma, became the 
first oncolytic immunotherapy to be approved by the United 
States (US) Food and Drug Administration (FDA) [1]. In 
the wake of FDA approval and following a subgroup analy-
sis of patients with stage IIIB–IVM1a melanoma from the 
Phase III study, talimogene laherparepvec also became the 
first oncolytic immunotherapy approach to be approved in 
Europe, where it is indicated for adults with unresectable 
stage IIIB, IIIC, or IVM1a melanoma with no bone, brain, 
lung, or other visceral disease [2, 3]. In Australia, the Ther-
apeutic Goods Administration has approved talimogene 
laherparepvec as monotherapy for the treatment of mela-
noma in patients with unresectable cutaneous, subcutane-
ous, or nodal lesions after initial surgery [4].
Mechanism of action
Talimogene laherparepvec was generated from herpes sim-
plex virus type 1 (HSV-1), a contagious, lytic, and human 
pathogen around 200 nm in diameter with a large genome 
(152  kb) that was considered a suitable vector due to its 
well-characterized biology [5–7]. To initiate infection, 
HSV-1 attaches to cell surface receptors before rapid fusion 
of the viral envelope with the cell membrane occurs, ena-
bling transport of the viral DNA to the cell nucleus [5]. 
Initial attachment is mediated by the interaction of viral 
glycoproteins with cell surface heparin sulfate [5]. This 
is followed by viral binding with cell surface receptors, 
such as nectin-1 and herpesvirus entry mediator A, which 
are broadly expressed across a wide variety of human cell 
types [5]. Talimogene laherparepvec is an attenuated form 
of HSV-1 that has been modified to diminish viral patho-
genicity as well as to induce selective tumor lysis and 
increase antigen presentation [8]. Specifically, both copies 
of the gene encoding ICP34.5 have been deleted, which is 
expected to reduce pathogenicity and provide tumor selec-
tive replication due to the oncogenic disruption of the 
protein kinase R (PKR) pathway [8]. In place of ICP34.5, 
the gene encoding human regulatory cytokine granulo-
cyte–macrophage colony-stimulating factor (GM-CSF) has 
been inserted [8]. GM-CSF enhances the immune response 
to tumors [8], attracts and induces myeloid precursor cells 
to proliferate and differentiate [9], and recruits and stimu-
lates dendritic cells [10]. Talimogene laherparepvec is 
also modified by deletion of the ICP47 gene, which pre-
vents ICP47 from blocking antigen presentation, thereby 
helping to restore immunogenicity [8]. This deletion also 
leads to elevated expression of the HSV US11 gene as an 
immediate early gene, rather than late gene, which enables 
US11 to block PKR activity before PKR is able to termi-
nate protein synthesis, leading to increased replication of 
ICP34.5-deleted HSV-1 in tumor cells [8, 11].
Following administration of talimogene laherparepvec, 
selective intratumoral replication and subsequent oncolysis 
directly destroys cancer cells and releases progeny viruses, 
tumor-associated antigens and danger-associated molecu-
lar factors [12]. The progeny viruses then infect other local 
tumor cells, intensifying the ‘danger’ signals and propagat-
ing the antitumor effect [8, 12]. GM-CSF helps prime and 
induce tumor-specific immunity by promoting the matu-
ration and function of dendritic cells, which may activate 
antitumor T cells through the presentation of the processed 
tumor-associated antigens. Activated T cells can then pro-
liferate and migrate to distant tumor sites, where they may 
recognize tumor cells with matching antigen profiles. These 
properties differentiate talimogene laherparepvec from 
other intralesional agents, which are in earlier stages of 
development and are often replication deficient (Table 1).
Preclinical and clinical experience
Preclinical models have demonstrated talimogene laher-
parepvec-induced tumor lysis and augmented antitumor 
immune responses in a number of different cancer cell lines 
and animal models [8, 21]. Data showing that HSV-1 anti-
gen and DNA are selectively expressed in tumors injected 
with talimogene laherparepvec [22] which provides evi-
dence that the direct antitumor effects of talimogene laher-
parepvec occur mainly at the injection site. In addition, 
the increased area occupied by CD8+ T cells within both 
injected and uninjected tumors show the development of 
an indirect systemic antitumor immune response following 
talimogene laherparepvec injection [23]. In murine mod-
els, both injected and uninjected tumors were reduced or 
cleared and mice also developed resistance to subsequent 
challenge with the same tumor cells [8, 21, 22]. Prolonged 
survival following treatment with talimogene laherparepvec 
was also seen in a mouse tumor model [22].
Clinical trials have demonstrated the safety and efficacy 
of talimogene laherparepvec in patients [6, 24, 25]. The 
first-in-human study was conducted in pre-treated patients 
with breast, head and neck, gastrointestinal cancers, and 
melanoma, to determine the safety profile and biological 
activity of talimogene laherparepvec and to identify a suita-
ble dose schedule for future studies [24]. Talimogene laher-
parepvec was well tolerated with no maximum-tolerated 
dose reached (which enabled a multi-dosing schedule to be 
defined) and biological activity (virus replication, GM-CSF 
expression, local reactions, and HSV-1 antigen-associated 
tumor necrosis) was observed [24].
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A Phase II trial evaluated the efficacy and safety of tali-
mogene laherparepvec in patients with unresectable, stage 
IIIC-IV malignant melanoma (clinicaltrials.gov identifier: 
NCT00289016) [25]. Melanoma was selected for this study 
due to the availability of accessible lesions for direct injec-
tion and because an active role for the immune system has 
been implicated in this type of cancer. The Phase II trial 
reported a 26% overall response rate (ORR) in talimogene 
laherparepvec-treated patients and limited toxicity [25]. 
Early studies also identified the accumulation of MART-
1-specific CD8+ T cells in both injected and uninjected 
lesions, suggesting both local and systemic immune activ-
ity [26].
These positive results led to the prospective, rand-
omized, open-label Phase III OPTiM trial (clinicaltrials.
gov identifier: NCT00769704) [6]. The trial included 436 
treatment-naïve and previously treated patients with unre-
sectable stage IIIB–IVM1c melanoma from May 2009 until 
July 2011. Patients were randomized at a two-to-one ratio 
to treatment with intralesional talimogene laherparepvec 
(n = 295) or subcutaneous recombinant GM-CSF (n = 141) 
[6]. GM-CSF was considered to be a valid comparator 
at the time the study was designed/conducted, as avail-
able data suggested that it has some antitumor activity in 
melanoma and is associated with minimal toxicity [27]. 
The primary endpoint for OPTiM was durable response rate 
(DRR), defined as the rate of complete response (CR) plus 
partial response (PR) beginning within 1 year of treatment 
and maintained for ≥6 months continuously, as assessed by 
an endpoint-assessment committee [6]. In the overall popu-
lation, talimogene laherparepvec significantly improved 
DRR compared with subcutaneous GM-CSF (16 vs 2%, 
respectively; p < 0.001), with efficacy most pronounced 
in patients with earlier-stage metastatic disease [6]. Spe-
cifically, the difference in DRR between talimogene laher-
parepvec and GM-CSF was greater in patients with stage 
IIIB/C (33 vs 0%) and IVM1a disease (16 vs 2%) compared 
with patients with stage IVM1b (3.1 vs 3.8%) and IVM1c 
(7.5 vs 3.4%) disease (Fig.  1) [6]. In the overall popula-
tion, a median survival difference of 23 vs 19 months was 
observed with talimogene laherparepvec vs GM-CSF (haz-
ard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.62, 
1.00; p = 0.051) (Fig. 1) [6]. Further analysis showed tali-
mogene laherparepvec’s effect on overall survival (OS) to 
be greater in patients with earlier-stage disease and in those 
with treatment-naïve disease (Fig.  1) [6]. In patients with 
stage IIIB–IVM1a melanoma, median OS was longer in 
the talimogene laherparepvec arm (41 months; 95% CI, 31 
Table 1  Other intralesional therapies in development or discontinued
HLA human leukocyte antigen, IL interleukin, MHC major histocompatibility complex, NA not reported
Agent Description and mode of action Replication 
competent
Trial phase Suitable for 
systemic 
delivery?
Allovectin-7 (velimogene aliplasmid) [13, 14] A plasmid/lipid complex encoding HLA-B7 and ß2 
microglobulin, both components of MHC-I
No Discontinued No
ALVAC GM-CSF [15] Viral vector system using recombinant canarypox 
virus for local GM-CSF gene expression; GM-
CSF activates dendritic cells, macrophages and 
granulocytes
No I No
ALVAC IL-2 [15] Viral vector system using recombinant canarypox 
virus for local IL-2 gene expression. IL-2 stimu-
lates T-cell proliferation, induces activation of 
cytotoxic T lymphocytes and natural killer cells
No I No
CVA21 (CAVATAK) [16] An oncolytic and immunotherapeutic strain of 
Coxsackievirus A21 that leads to cell lysis and 
enhancement of antitumor immune responses
Yes II Yes
Pexastimogene devacirepvec (JX-594) [17] Modified vaccinia virus with thymidine kinase 
deletion and GM-CSF insertion; stimulates anti-
tumor immunity
Yes I/II Yes
PV-10 [18] A water-soluble xanthene dye that, when given as 
an intralesional injection, leads to tumor ablation
No III No
TG1024 (adenovirus IL-2) [19] Recombinant adenovirus construct, expressing 
genes for IL-2, which stimulates T-cell prolifera-
tion, induces activation of cytotoxic T lympho-
cytes and natural killer cells
No I/II No
Xenogenic plasmid IL-12 [20] Plasmid DNA encoding IL-12, which enhances 
the immune capacity of natural killer cells and 
T cells
No I/II No
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months, not evaluable), compared with the GM-CSF arm 
(21.5 months; 95% CI, 17, 30 months). Talimogene laher-
parepvec was well tolerated in OPTiM; the most common 
adverse events (AEs) occurring in patients receiving tali-
mogene laherparepvec were fatigue, chills, and pyrexia [6]. 
The majority (89%) of AEs were grade 1 or 2. Cellulitis 
was the only grade 3 or 4 AE to occur in ≥2% of talimo-
gene laherparepvec-treated patients, and no fatal treatment-
related AEs occurred during the study [6].
There is room to increase these observed benefi-
cial effects with talimogene laherparepvec. A treatment 
approach that shows promise is the combination of differ-
ent immunotherapies, which has the potential to improve 
efficacy relative to either therapy alone [29]. In this review, 
we discuss the potential for talimogene laherparepvec 
to be used in combination with other immunotherapies 
and revisit the ongoing and upcoming talimogene laher-
parepvec combination trials.
Rationale for combining talimogene laherparepvec 
with other immunotherapies
Talimogene laherparepvec has considerable local immune 
activity, with intralesional administration resulting in 
responses (≥50% regression) in 64% of injected lesions 
during OPTiM [30]. A 50% reduction in tumor size was 
also seen in 34% of non-injected non-visceral lesions and 
in 15% of visceral lesions, indicating that talimogene laher-
parepvec also induces systemic antitumor immunity and 
response [30]. While activity was observed at distant metas-
tases, it has been hypothesized that combining talimogene 
laherparepvec with other systemic immunotherapies may 
further enhance the efficacy of both agents. In this regard, 
talimogene laherparepvec’s potentially complementary 
mechanism of action with other approved immunotherapies 
supports its use in combination clinical trials (Fig. 2). The 
oncolytic properties of talimogene laherparepvec result in 
the release of tumor-derived antigens in an immune stimu-
latory microenvironment, local production of GM-CSF, and 
cross-priming of CD8+ T-cell responses by dendritic cells, 
which facilitate an immune response against the tumor 
[12]. However, immune responses can be evaded through 
the expression of immunosuppressive checkpoint receptors 
on the surface of T cells, such as CTL antigen-4 (CTLA-4) 
and programmed cell death 1 (PD-1). Checkpoint inhibi-
tors, including CTLA-4 inhibitors (e.g., ipilimumab) and 
PD-1 receptor/ligand inhibitors (e.g., pembrolizumab, 
nivolumab, and atezolizumab), have established efficacy, 
acting systemically to enhance T-cell recruitment and pre-
vent exhaustion of activated T cells [31–36]. CTLA-4 and 
PD-1/PD-L1 blockade can also reduce T-regulatory cell 
function, which may contribute to an antitumor response 
[35]. Combining talimogene laherparepvec with immune 
checkpoint inhibitors, therefore, has potential to augment 
tumor-specific immune responses and enhance the antitu-
mor activity compared with either treatment alone. In this 
respect, a preclinical study demonstrated that an injected 
oncolytic immunotherapy combined with CTLA-4 block-
ade had enhanced activity in local and distant tumors com-
pared with either agent alone [37].
The concept of combining immunotherapies with dif-
fering mechanisms of action was recently demonstrated 
in a randomized, double-blind, Phase III study assessing 
ipilimumab in combination with nivolumab in melanoma 
[29]. The median progression-free survival (PFS) was 11.5 
months with combination therapy, versus 2.9 months with 
ipilimumab alone and 6.9 months with nivolumab alone 
[29]. However, significantly more treatment-related grade 3 
or 4 AEs, including immune-related AEs, were seen with 
ipilimumab plus nivolumab (55%) compared with ipili-
mumab monotherapy (27%) or nivolumab monotherapy 
(16%) [29]. Non-overlapping toxicity profiles are important 
for patients to successfully tolerate treatment combinations. 
Therefore, the relatively low rate of grade 3 or 4 AEs with 
talimogene laherparepvec supports its use in combination 
with other therapies [6].
Available data from combination studies 
of talimogene laherparepvec in melanoma
Based on the rationale for combining talimogene laher-
parepvec with agents that can promote T-cell responses, 
talimogene laherparepvec has been evaluated in clinical tri-
als for melanoma in combination with ipilimumab or pem-
brolizumab. Data on combination therapy with intralesional 
Fig. 1  Key efficacy data from the Phase III talimogene laherparepvec 
OPTiM clinical trial [6]*. a Duration of response for all patients with 
response per endpoint-assessment committee (EAC) assessment. 
Duration of response was defined as longest period of response from 
entering response to first documented evidence of patient no longer 
meeting criteria for response. Arrows indicate patients for whom 
duration of response was censored at last tumor assessment, because 
there was no evidence (per EAC assessment) that their response had 
ended. b DRR in patient subgroups defined by key baseline character-
istics. c Primary analysis of OS in intent-to-treat population. d OS in 
patient subgroups defined by key baseline characteristics. *Reprinted 
with permission from Andtbacka et  al. [6]. © 2017 American Soci-
ety of Clinical Oncology. All rights reserved. CR complete response, 
DRR durable response rate, ECOG Eastern Cooperative Oncology 
Group, GM-CSF granulocyte–macrophage colony-stimulating factor, 
HR hazard ratio, HSV-1 herpes simplex virus-1, OS overall survival, 
PS performance status, PR partial response, T-VEC talimogene laher-
parepvec. *p < 0.001 per Gail and Simon [28] quantitative treatment 
by covariate interaction test (for DRR). †One patient in the talimo-
gene laherparepvec arm had unknown disease stage. ‡Twelve patients 
in the GM-CSF arm and four in the talimogene laherparepvec arm 
had unknown ECOG status
◂
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therapies have, until recently, been lacking; therefore, these 
studies provide a benchmark for future research.
Ipilimumab combined with talimogene laherparepvec
Ipilimumab is indicated in both Europe and the US for the 
treatment of advanced (unresectable or metastatic) mela-
noma in adults [32, 38] (see Camacho LH [39] for a recent 
review). It is a IgG1 monoclonal antibody directed against 
CTLA4, which blocks immunosuppression mediated by the 
interaction of B7 ligands (B7.1 and B7.2) on antigen-pre-
senting cells and CTLA4 on CD8+ and CD4+ T cells and 
might deplete immunosuppressive regulatory T cells [36, 
40, 41]. This disinhibits the expansion of T-cell responses, 
promoting the production of autoreactive T cells [36]. 
When administered as a monotherapy, ipilimumab demon-
strated significant efficacy in patients with unresectable and 
metastatic melanoma, although immune-related AEs were 
common [42]. In a Phase III trial, ipilimumab was asso-
ciated with a response rate of 10.9% and a median OS of 
10.1 months [42]. OS data from a pooled analysis of ten 
prospective and two retrospective observational studies of 
ipilimumab, including two Phase III trials, indicate a 3-year 
survival rate of 22% with ipilimumab [43]. The survival 
rate plateaus around year 3 and is maintained up to 10 years 
in some patients [43]. Consequently, while efficacious, the 
low response rate and the frequency of severe AEs limit its 
use as a monotherapy.
The addition of ipilimumab to talimogene laherparepvec 
has the potential to enhance the priming and activation 
of T cells: dendritic cells present tumor antigens that are 
released following the oncolytic replication of talimogene 
laherparepvec (Fig.  2) [8, 36]. Talimogene laherparepvec 
was evaluated in combination with ipilimumab in the Phase 
Ib portion of an ongoing Phase Ib/II clinical trial (Study 
20110264; clinicaltrials.gov identifier: NCT01740297). For 
this portion of the study, 21 patients were screened and 19 
patients were enrolled across five US sites from February 
2013 to July 2013 [44]. Patients with unresectable, inject-
able stage IIIB–IVM1c melanoma, who had received no 
prior systemic therapy (except prior adjuvant therapy ≥ 6 
months from last therapy) were included in the study [44]. 
Priming and
activation
Ipilimumab
Release of
cancer cell antigens
Talimogene laherparepvec
3
1
Cancer antigen
presentation
Talimogene
laherparepvec
2
Trafficking of
T cells to tumors4
Infiltration of
T cells into tumors
Lymph node
Blood
vessel
Tumor
5
Recognition of
cancer cells
by T cells
Pembrolizumab
6
Killing of cancer cells
Pembrolizumab
7
Fig. 2  Mechanism of action of talimogene laherparepvec combined 
with ipilimumab or pembrolizumab [36]*. Talimogene laherparepvec 
would act to enhance the cancer–immunity cycle through inducing 
the death of tumor cells causing the release of TDAs. Talimogene 
laherparepvec would also enhance the activation and recruitment 
of dendritic cells through the production of GM-CSF, thereby caus-
ing increased processing of TDAs by the dendritic cells. Ipilimumab 
could enhance the action of talimogene laherparepvec to further boost 
the cancer–immunity cycle by enhancing the priming and activation 
of T cells by dendritic cells presenting TDAs. Pembrolizumab could 
enhance the action of talimogene laherparepvec to further boost the 
cancer–immunity cycle by enhancing the recognition and killing of 
tumor cells by T cells. *Reprinted from Immunity, Volume 39, Chen 
and Mellman [36], Page 7, Copyright (2016), with permission from 
Elsevier. GM-CSF granulocyte–macrophage colony-stimulating fac-
tor, TDA tumor-derived antigen
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Talimogene laherparepvec was administered intralesionally 
as monotherapy at an initial dose of  106 PFU/ml and then 
at  108 PFU/ml every 2 weeks from week 4 [44]. Intrave-
nous ipilimumab, administered at a dose of 3 mg/kg every 
3 weeks for four infusions, began at the time of the third 
dose of talimogene laherparepvec [44]. Talimogene laher-
parepvec was continued until CR, all injectable tumors dis-
appeared, progressive disease (PD) per modified immune-
related response criteria (irRC), or drug intolerance [44]. 
The primary endpoint was the incidence of dose-limiting 
toxicities (DLTs), defined as any treatment-related non-lab-
oratory grade ≥4 AE, grade ≥4 immune-mediated dermati-
tis or endocrinopathy, and grade ≥3 immune-mediated AE 
of any other type (e.g., pneumonitis, pancreatitis, nephritis, 
uveitis, and vasculitis).
No DLTs were observed during the DLT evaluation 
period or throughout the Phase Ib portion of the study 
[44]. Grade 3/4 treatment-related AEs were seen in 26% of 
patients (16% were attributed to talimogene laherparepvec 
and 21% were attributed to ipilimumab) (Table  2) [44]. 
ORR was 50% (95% CI, 26.0 to 74:0), which was almost 
double that observed in OPTiM (Table  2) [6, 42, 44]. 
This ORR was also higher than that observed in a Phase 
III trial with ipilimumab alone (data not shown), although 
it should be noted that patients were not required to have 
injectable disease in that Phase III study, so it is likely to 
have included a somewhat different patient population. 
Four patients (22%) had a confirmed CR [44], relative to 
1.5% of patients treated with ipilimumab monotherapy in a 
Phase III trial [42]. All four patients were still in CR after a 
year [44]. Overall, 44% of patients in Study 20110264 had 
a DRR (defined as duration of response [DOR] lasting ≥6 
months, where DOR is the interval from a first confirmed 
objective response to confirmed PD), compared with 16% 
of patients experiencing a DRR (defined as objective 
response lasting continuously ≥6 months) in OPTiM [6, 
44]. Following the combination treatment, probabilities of 
18-month PFS and OS were 50 and 67%, respectively [44].
There was evidence of immune modulation during the 
study and total CD8 + T cells and activated CD8 + T cells 
were significantly increased from baseline following treat-
ment with talimogene laherparepvec [44]. The increase 
in activated CD8+ T cells seemed to be greater in those 
patients experiencing disease control rather than pro-
gressive disease [44]. However, this differentiation was 
lost after ipilimumab administration [44]. CD4 + T cells 
expressing ICOS (inducible T-cell costimulator), an activa-
tion marker upregulated by CTLA-4 blockade, significantly 
increased from baseline at weeks 9 and 15 after ipilimumab 
was given, but not during the talimogene laherparepvec 
monotherapy period [44]. These immune findings indicate 
that T-cell responses with talimogene laherparepvec and 
ipilimumab may be complementary.
There are inherent limitations with comparing data 
across trials. For example, the distribution of patients 
across the disease stages differs between Study 20110264 
and OPTiM and different assessment criteria were used. 
Nonetheless, these early phase findings suggest that the 
efficacy of combined ipilimumab and talimogene laher-
parepvec may be greater than that seen historically with 
ipilimumab or talimogene laherparepvec monotherapy [6, 
42, 44].
Pembrolizumab combined with talimogene 
laherparepvec
Pembrolizumab, recently reviewed by Khoja et al. [47], is 
indicated for the treatment of advanced (unresectable or 
metastatic) melanoma in adults (Europe and US) and for 
disease progression following ipilimumab and, if BRAF 
V600 mutant, a BRAF inhibitor (US) [33, 48]. Pembroli-
zumab is a monoclonal IgG4 antibody directed against 
PD-1, which blocks the immunosuppression mediated 
by the interaction of PD-L1 on tumor cells and PD-1 on 
CD8+ and CD4+ T cells, therefore, improving tumor cell 
recognition by T cells [36, 40, 49]. In the randomized 
Phase III KEYNOTE-006 trial (clinicaltrials.gov identi-
fier: NCT01866319) that assessed the efficacy of pembroli-
zumab vs ipilimumab in advanced melanoma, pembroli-
zumab improved PFS, OS, and ORR and was associated 
with fewer grade ≥3 AEs [50].
The addition of pembrolizumab to talimogene laher-
parepvec has the potential to enhance the systemic antitu-
mor response by enhancing the recognition and killing of 
tumor cells by T cells that have been primed as a result of 
talimogene laherparepvec injection (Fig.  2) [8, 36]. Tali-
mogene laherparepvec was evaluated in combination with 
pembrolizumab in the Phase Ib portion of the Phase Ib/
III clinical trial, called MASTERKEY-265 (clinicaltrials.
gov identifier: NCT02263508) [45, 51]. For this portion of 
the study, 21 patients with stage IIIB–IVM1c melanoma 
with injectable lesions and no prior systemic therapy were 
enrolled from December 2014 to March 2015 at 11 insti-
tutions in Europe and the US [45, 51]. Talimogene laher-
parepvec was administered as monotherapy at an initial 
dose of  106 PFU/ml and then at  108 PFU/ml every 2 weeks 
from week 3 [45]. Pembrolizumab was administered intra-
venously at a dose of 200 mg every 2 weeks, commencing 
at the time of the third dose of talimogene laherparepvec 
[45]. Treatment with both therapies was continued for up 
to 2 years or until (whichever occurred first) CR or PD 
per modified irRC, intolerance, or, for talimogene laher-
parepvec only, when there are no longer any remaining 
injectable lesions [51]. The primary endpoint for the Phase 
Ib portion of the trial was the incidence of DLTs, with 
the evaluation period defined as 6 weeks from the initial 
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administration of pembrolizumab [45, 51]. Data cutoff for 
the Phase Ib safety and efficacy results was January 4, 2016 
[45]. The study met its primary endpoint with no DLTs 
observed during the monitoring period [45]. There was no 
additional toxicity with the combination treatment com-
pared with that expected for the monotherapies (Table 2).
Table 2  Key safety and efficacy data from the Phase 1b arm of clini-
cal trial NCT01740297 (investigating ipilimumab in combination 
with talimogene laherparepvec in melanoma), the Phase 1b arm of 
clinical trial NCT02263508 (investigating pembrolizumab in combi-
nation with talimogene laherparepvec in melanoma), and historical 
data for talimogene laherparepvec monotherapy from the Phase III 
OPTiM clinical trial in melanoma*
CR complete response, DCR disease control rate, DRR durable response rate, ECOG Eastern Cooperative Oncology Group, LDH lactate dehy-
drogenase, NA not applicable, NR not reported, ORR overall response rate, OS overall survival, PD progressive disease, PFS progression-free 
survival, PR partial response, SD stable disease, TRAE treatment-related adverse event, ULN upper limit of normal
*The data are derived from three independent clinical trials; comparisons across trials should be interpreted with caution. †Data are for grade 3 
TREAs only; one grade 4 TRAE (pneumonitis, pembrolizumab related) was reported. ‡In of clinical trial NCT01740297, DRR is defined as a 
duration of response (DOR) lasting ≥6 months, where DOR is the interval from a first confirmed objective response to confirmed PD. In OPTiM, 
DRR was defined as an objective response lasting continuously ≥6 months. #Tumor response defined as ≥50% regression
Talimogene laher-
parepvec + ipilimumab 
[44]
Talimogene laher-
parepvec + pembroli-
zumab [45]
Talimogene laherparepvec monotherapy 
[HISTORICAL DATA FROM OPTiM] [6, 
30, 46]
Baseline characteristics
Disease stage
 IIIB 1 (5) 1 (5) 22 (8)
 IIIC 3 (16) 7 (33) 66 (22)
 IVM1a 4 (21) 2 (10) 75 (25)
 IVM1b 5 (26) 3 (14) 64 (22)
 IVM1c 6 (32) 8 (38) 67 (23)
 Unknown 0 (0) 0 (0) 1 (<1)
ECOG performance status
 0 14 (74) 19 (91) 209 (71)
 1 5 (26) 2 (10) 82 (28)
 Unknown 0 (0) 0 (0) 4 (1)
LDH
 ≤ULN 15 (79) 16 (76) 266 (90)
 >ULN 1 (5) 5 (24) 15 (5)
 Unknown 3 (16) 0 (0) 14 (5)
Safety findings
Grade 3/4 TRAE, N (%)
 Any event 5 (26) 7 (33)† 33 (11)
 Any attributed to talimogene laherparepvec 3 (16) 4 (19) 33 (11)
 Any attributed to checkpoint inhibitor 4 (21) 6 (29)† NA
Efficacy findings
ORR, n (%) 9 (50) 12 (57) 78 (26)
CR, n (%) 4 (22) 5 (24) 32 (11)
PR, n (%) 5 (28) 7 (33) 46 (16)
SD, n (%) 4 (22) 3 (14) 134 (45)
PD, n (%) 5 (28) 6 (29) 62 (21)
DRR, n (%)‡ 8 (44) NR 48 (16)
DCR, N (%) NR 15 (71) 225 (76)
12-month PFS, % 50 71 NR
12-month OS, % 72 NR 74
Tumor response at the lesion level, %#
 Injected lesions 74 80 64
 Non-injected lesions 52 35 NR
 Non-visceral 54 45 34
 Visceral 50 28 15
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The combination therapy was associated with clinical 
benefit with a confirmed ORR of 57% and confirmed CR 
rate of 24% (Table 2) [45]. This ORR was greater than pre-
viously seen with pembrolizumab in a Phase III trial (34%) 
and with talimogene laherparepvec seen in OPTiM (26%)—
although it should be recognized that cross-trial comparisons 
are associated with limitations, particularly as these stud-
ies had different designs and patient populations [6, 439]. 
Unconfirmed ORR was 67%, and unconfirmed CR rate was 
29% [45]. Median PFS was not reached during the study, 
with 71% of patients being progression free at 6 months; dis-
ease control rate (DCR) was 71% [45]. As seen previously, 
an increase in circulating cytotoxic T cells (CD3+/CD8+) 
was observed after the start of talimogene laherparepvec 
monotherapy, as well as an upregulation of PD-1 and TIM-3 
on these cells [45]. These results need careful interpretation, 
since melanoma patients with skin metastases often present 
with a less aggressive clinical course. However, the data still 
indicate that talimogene laherparepvec primes the immune 
response to enable an optimum response to pembrolizumab. 
Overall, these early findings suggest increased efficacy with 
combined pembrolizumab and talimogene laherparepvec 
treatment compared with pembrolizumab or talimogene 
laherparepvec monotherapy [6, 45, 50].
Summary of available data from combination studies 
of talimogene laherparepvec in melanoma
Based on these early phase data, combining talimogene 
laherparepvec with ipilimumab or pembrolizumab may 
result in greater efficacy for patients than either therapy 
alone [6, 42, 44, 45, 50]. The ORR with talimogene laher-
parepvec plus either ipilimumab or pembrolizumab was 
around double that seen with talimogene laherparepvec 
alone, while the rate of CRs was more than doubled [6, 44, 
45]. The combination clinical trials have not raised addi-
tional safety considerations, with safety profiles in line with 
those expected for either of these drugs as monotherapies.
Ongoing talimogene laherparepvec combination 
studies in melanoma and other tumor types
Melanoma
Based on the promising early results seen to date for tali-
mogene laherparepvec combination therapy in melanoma, 
a number of clinical trials are ongoing (Table 3).
Ipilimumab plus talimogene laherparepvec
The Phase II portion of the Phase Ib/II clinical trial 
mentioned above (Study 210110264; clinicaltrials.gov 
identifier: NCT01740297), evaluating talimogene laher-
parepvec in combination with ipilimumab for patients 
with stage IIIB–IVM1c melanoma, includes a rand-
omized design in which patients are receiving talimogene 
laherparepvec and ipilimumab or ipilimumab alone [41]. 
Approximately 200 patients across 40 sites in Europe and 
the US have been enrolled (enrolment is now complete) 
[52]. Patients are being treated with talimogene laher-
parepvec until CR, all injectable tumors have disappeared, 
disease progression per a modified irRC, or intolerance of 
study treatment [52]. The primary outcome is to evaluate 
efficacy as assessed by ORR [52]. Secondary outcomes 
include safety, best overall response, DCR, DRR, DOR, 
time to response (TTR), PFS, resection rate, OS, and land-
mark OS by year [52]. An interim analysis from this study 
was recently performed [54]. In the efficacy set, which con-
sisted of 82 patients with ≥ 48 weeks of follow-up, the con-
firmed ORR for talimogene laherparepvec and ipilimumab 
was 36 versus 17.5% (ipilimumab alone), while the uncon-
firmed ORR was 50% (talimogene laherparepvec plus 
ipilimumab) versus 27.5% (ipilimumab) [54]. For the 165 
patients in the Phase II safety set, no unexpected AEs were 
observed. The most common treatment-emergent AEs were 
chills, fatigue, pyrexia, pruritus, and rash. Grade 3/4 treat-
ment-emergent AEs were similar between arms [54]. The 
data suggest that talimogene laherparepvec combined with 
ipilimumab has greater efficacy than either agent alone 
without additional safety concerns [54]. The primary analy-
sis of response will occur 6 months after the last patient is 
randomized.
Pembrolizumab plus talimogene laherparepvec
The Phase III portion of the Phase Ib/III MASTER-
KEY-265 clinical trial (clinicaltrials.gov identifier: 
NCT02263508) is evaluating the safety and efficacy of tali-
mogene laherparepvec in combination with pembrolizumab 
vs pembrolizumab plus intralesional placebo (talimogene 
laherparepvec formulation excipients) in patients with 
IIIB–IVM1c melanoma, and is currently enrolling patients 
[51]. Patients are being recruited across 21 sites in Europe, 
the US, and Australia [51]. It is expected that 660 patients 
will be randomized 1:1 to each treatment arm [51, 53]. 
Patients will be treated until 24 months from the date of the 
first dose of pembrolizumab or end of treatment due to dis-
appearance of injectable lesions (talimogene laherparepvec/
placebo only), confirmed CR (pembrolizumab discontinu-
ation after confirmed CR is optional), disease progression 
per irRC-RECIST, or intolerance of study treatment [51]. 
Final analysis will occur 5 years after the last patient is 
enrolled in the Phase III portion of the study [53]. The pri-
mary outcome is to evaluate efficacy as assessed by PFS 
(centrally reviewed using modified RECIST 1.1) and OS 
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and secondary outcomes include safety, ORR DCR, DRR, 
DOR, PFS (by modified irRC-RECIST), OS, and patient 
reported outcomes [51, 53].
Other tumor types
Talimogene laherparepvec combination studies in addi-
tional cancers have been initiated. At present, there are 
ongoing studies investigating talimogene laherparepvec in 
combination with immunotherapies in solid tumors other 
than melanoma, including a Phase 1b/III multicenter, ran-
domized, open-label trial (MASTERKEY-232 [clinicaltri-
als.gov identifier: NCT02626000]) in recurrent or meta-
static squamous cell carcinoma of the head and neck. In 
the Phase Ib part of this trial, talimogene laherparepvec is 
being administered in combination with pembrolizumab to 
approximately 40 patients [55]. The primary endpoint will 
be DLT, which will be evaluated based on the first 18 DLT-
evaluable patients [55]. An expansion cohort of an addi-
tional 22 treated patients will be enrolled to further evaluate 
the safety and to estimate the efficacy of the combination of 
talimogene laherparepvec with pembrolizumab to support a 
decision to initiate the Phase III study [55].
Conclusions and future perspectives
Oncolytic immunotherapy is an active area of ongoing 
research with talimogene laherparepvec at the forefront of 
the field [1, 2]. Based on complementary mechanisms of 
action, clinical trials are in progress to extend the proven 
therapeutic benefit seen with talimogene laherparepvec 
monotherapy through combinations with other immuno-
therapies. The initial data from early studies in melanoma 
suggest that combining talimogene laherparepvec with 
ipilimumab or pembrolizumab is well tolerated and more 
efficacious than treatment with the individual therapies 
alone, with evidence that complementary mechanisms 
of action are responsible for the enhanced effects. The 
combination with pembrolizumab and talimogene laher-
parepvec is also being studied in other cancer types, such 
as SCCHN. Studies of solid tumors other than melanoma 
will help to ascertain whether talimogene laherparepvec 
has the capacity to engage the immune system in tumors 
that are currently not responsive to immunotherapy. Such 
tumors do not usually respond well checkpoint inhibitors, 
but if talimogene laherparepvec can effectively initiate 
an immune response that can be modulated by check-
point inhibitors, this combination therapy may become an 
option for a larger patient population.
There is also potential for future combina-
tion trials of talimogene laherparepvec with other 
immunotherapies that are currently in development. For 
example, agents that target immunosuppressive tumor-
associate macrophages [56], immune-activating agents, 
such as cytokines [57] and STING (Stimulator of Inter-
feron Genes)-activating agents [58], and agents that tar-
get T-cell costimulatory receptors molecules [59] could 
potentially be investigated in combination with talimo-
gene laherparepvec in the future. Furthermore, radiation 
therapy or chemotherapy may also prove to be effective 
partners for talimogene laherparepvec or talimogene 
laherparepvec combination regimens [60–62]. In addi-
tion to direct tumor cell cytotoxicity, localized radiation 
therapy and chemotherapeutic agents can also lead to 
systemic responses through immunomodulatory effects 
both on the tumor and the microenvironment [61, 63, 64]. 
This process can prime tumors for an immune-mediated 
response and may enhance efficacy as part of a combi-
nation strategy. Indeed, combining radiation therapy with 
checkpoint inhibitors has demonstrated promising results 
[63, 65], as have combinations of oncolytic virotherapies 
with chemotherapies [61, 64], and trials of talimogene 
laherparepvec combined with radiotherapy or chemother-
apy are being initiated [66–69]. Finally, increased dura-
ble disease control might also be achieved by combining 
talimogene laherparepvec with targeted therapies, such as 
BRAF inhibitors and vascular endothelial growth factor 
inhibitors, and this could be useful in  situations where 
long-term effectiveness can otherwise be limited by the 
emergence of resistance [70].
In the future, precision/personalized therapy may be 
achieved via talimogene laherparepvec combination ther-
apy by tailoring the choice of combination agent to the 
individual patient and tumor characteristics, and studies 
are underway to identify potential predictive biomark-
ers. Further clinical research will help establish the full 
potential for talimogene laherparepvec in combination 
with other agents for the treatment of cancer.
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